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Abstract: Poor solubility is one of the key reasons for the poor bioavailability 
of carbamazepine drugs. This study considers formulation of solid surfactant 
systems with carbamazepine, in order to increase its dissolution rate. Solid-
state surfactant systems were formed by application of fractional experimental 
design. Poloxamer 237 and Poloxamer 338 were used as the surfactants and 
Brij® 35 was used as the co-surfactant. The ratios of the excipients and carba-
mazepine were varied and their effects on the dissolution rate of carbamazepine 
were examined. Moreover, the effects of the addition of natural (diatomite) and 
a synthetic adsorbent carrier (Neusilin® UFL2) on the dissolution rate of carba-
mazepine were also tested. The prepared surfactant systems were characterized 
and the influences of the excipients on possible changes of the polymorphous 
form of carbamazepine examined by application of analytical techniques (DSC, 
TGA, FT-IR and PXRD). It was determined that an appropriate selection of the 
excipient type and ratio could provide a significant increase in the carbama-
zepine dissolution rate. By application of analytical techniques, it was found 
that the employed excipients induce a transition of carbamazepine into the 
amorphous form and that the selected sample was stable for three months, 
when kept under ambient conditions. 
Keywords: poloxamer; neusilin; diatomite; solid surfactant drug delivery sys-
tems; polymorphous transition. 
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INTRODUCTION 
According to Ku and Dulin, the number of new drug candidates that exhibit 
poor aqueous solubility has increased by up to 70 %.1 The dissolution of poorly 
soluble drugs is the rate-limiting step for drug absorption and bioavailability. 
Therefore, formulation of drug delivery systems that promote drug release could 
be a useful approach to improve absorption and oral bioavailability.2 A number 
of alternative technologies have been developed to overcome the drawbacks 
associated with poor aqueous solubility, for example, decreases in the particle 
size, the use of the amorphous form of the active pharmaceutical ingredient, solid 
dispersions, lipid-based formulations, surfactant application, cyclodextrin com-
plexation, etc.3–8  
In recent years, the application of surfactants has been widely used in the 
formulation of self-emulsifying drug delivery systems (SEDDS),9 self-nano-
emulsifying drug delivery systems (SNEDDS)10 and self-microemulsifying drug 
delivery systems (SMEDDS),11 as well as in the formulation of surfactant sys-
tems.12 According to the Plouton classification system of lipid formulations, a 
lipid formulation type IV consists of systems containing only surfactants without 
the addition of lipid excipients (e.g., surfactant systems).2 Such surfactant sys-
tems (consisting of drug, surfactants and co-surfactants), in contact with gastro-
intestinal fluids, allow drug solubilization and subsequent absorption.2  
Poloxamers are non-ionic polyoxyethylene–polyoxypropylene block copoly-
mers widely used in pharmaceutical technologies as gelling, emulsifying or solu-
bilizing agents.13–15 They are also frequently used in the formulation of solid 
dispersions.16 Due to their good solubilization capacities, poloxamers are com-
monly used in the creation of SEDDS.17 Brij® 35 is commonly used as a sur-
factant or co-surfactant in oral drug delivery systems with demonstrated imp-
roved drug solubility and bioavailability.18–20  
Nowadays, porous carriers with a large surface area are used in order to imp-
rove dissolution and bioavailability of poorly soluble drugs.11,21 Most frequently, 
such carriers are of synthetic origin (for example magnesium aluminometasilicate 
or porous silica). However, carriers of natural origin, such as diatomite (natural 
silica) are playing the leading role. Diatomites, as a new potential drug carrier, 
have several advantages in comparison to synthetic silicas: biocompatibility 
arising from their natural origin, thermal stability, chemical inertness and low 
cost. Additionally, the complex 3-dimensional (3-D) architecture of silica walls, 
called frustules, with highly ordered porous structures and high specific surface 
areas, provide for potential diffusion and controlled drug release.22,23 Like many 
complex silicates, the surface of Neusilin has different types of silanol groups, 
which make it a potential proton donor as well as an acceptor. The hydrogen 
bonding potential of silanols in the local environment on silica surfaces is well 
documented.24–26 
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Carbamazepine (CBZ) is a substance with poor water solubility (0.17 mg 
mL–1 at 24 °C) and high permeability.27,28 Based on its characteristics, it is clas-
sified into class II of the Biopharmaceutics Classification System (BCS).29 After 
oral administration, its gastrointestinal absorption is slow and irregular due to 
poor solubility in water, leading to incomplete bioavailability.27,28 CBZ is inter-
esting as a model substance not only because of its poor solubility, but also 
because it exists in multiple polymorphous forms, i.e., 4 crystalline forms, 1 hyd-
rate and an amorphous form. Transition from one to another form during the for-
mulation process in the presence of certain excipients is possible without changes 
in its stability.27,30,31 
The objective of this study was the formulation of a solid surfactant system 
with increased dissolution rate of CBZ. Fractional factorial design was applied in 
order to evaluate the influence of the following variables on the drug release: a) 
the type of poloxamer as surfactant (Poloxamer 237 and Poloxamer 338), b) the 
ratio of Brij® 35 as a co-surfactant, c) the type and ratio of the adsorption carrier 
(Neusilin UFL2 or Diatomite) and d) the ratio of the drug. 
Analysis of potential polymorphous transitions of CBZ was conducted by 
application of several analytical techniques, i.e., differential scanning calorimetry 
(DSC), thermal gravimetric analysis (TGA), powder X-ray diffraction analysis 
(PXRD) and Fourier transform infrared (FT-IR) spectroscopy. 
EXPERIMENTAL 
Materials 
Poloxamer 237 (Kolliphor™ P 237) and poloxamer 338 (Kolliphor™ P 338) were kindly 
donated by BASF ChemTrade GmbH (Burgbernheim, Germany). Polyoxyethylene(23)lauryl 
ether (Brij® 35) was obtained from Sigma–Aldrich, Germany. Magnesium aluminometa-
silicate (Neusilin® UFL2) was gifted by Fuji Chemical Industry (Toyama, Japan). Diatom 
porous silica particles of different particle size: 1–2 µm (10 %), 10 µm (60 %) and 30–50 µm 
(30 %) were obtained from Mount Sylvia, Pty. Ltd., Australia. CBZ (Ph. Eur. 8.0) was used as 
a model of a poorly soluble active ingredient. Double-distilled water was used in all expe-
riments. 
Methods 
Preparation of solid surfactant systems. All formulations were prepared by melting a 
mixture of surfactant and co-surfactant at 60 °C. CBZ was then added to the molten mass 
under vigorous stirring until a homogenous dispersion was obtained. The dispersion was then 
rapidly cooled on an ice bath to solidify and subsequently pulverized with a pestle and mortar, 
before being sieved through a 300-μm sieve. The sieved mixtures were mixed with an adsor-
bent carrier (Neusilin® UFL2 or diatomites) and the final formulations were thus obtained. 
These formulations were tested with regard to the CBZ dissolution rate, which provided 
dissolution rate profiles for each formulation. 
Two sets of experiments were conducted. In the first set of experiments, the individual 
effects of the excipients on the CBZ dissolution rate were investigated through a screening 
study. The following binary and ternary mixtures were prepared: Poloxamer 338/CBZ 
(80/20); Poloxamer 338/CBZ/Neusilin® UFL2 (40/10/50); Brij® 35/CBZ (80/20); Brij® 
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35/CBZ/Neusilin® UFL2 (40/10/50), in order to determine the individual effect of the exci-
pients on the CBZ dissolution rate. 
In the second set of experiments, fractional factorial experimental design was applied 
(25-2) for testing the influence of the formulation factors on the CBZ dissolution rate from the 
solid surfactant systems. The input parameters and the levels at which they were varied are 
given in Table I. The experimental plan (according to 25-2 factorial design) is given in Table 
S-I of the Supplementary material to this paper. According to the experimental plan, a mixture 
of CBZ, Brij® 35 and poloxamer (comprising the surfactant system) was first created, in the 
appropriate mass ratio, their individual ratios adding up to 100 %. The adsorbent carrier was 
added to this mixture at a later stage. The prepared surfactant system/adsorption carrier ratio 
was varied at two levels: 66.67/33.33 and 33.33/66.67 (Table I). The percentages of released 
CBZ were followed as output parameters after 10, 20, 30, 45, 60 and 120 min (Y1–Y6). The 
influence of the investigated input parameters on the output parameters (i.e., factor effects), 
according to the 25-2 factorial design, was calculated by fitting the results into the linear model:  
 y = β0 + β1X1 + β2X2 + β3X3 + β4X4 + β5X5 + ε (1) 
where y is the output parameter, X1–X5 are the input parameters, β1–β5 are the effects of 
individual input parameters on the output parameter (factor effects) and ε is the experimental 
error. 
TABLE I. Varied input parameters in the second set of experiments 
Parameter Low level (–1) High level (+1) 
Type of Poloxamer (X1) P237 P338 
Brij® 35 ratio (X2), % 10 20 
CBZ ratio (X3), % 10 20 
Type of adsorption carrier (X4) Neusilin UFL2 Diatomites 
Adsorption carrier ratio (X5), % 33.33 66.67 
Design Expert software (version 7.0.0; Stat-Ease, Inc., Minneapolis, MN, U.S.A.) was 
applied.  
After performing the second set of experiments, the solid surfactant system with the 
fastest CBZ release was selected. In the selected formulation, the percentage of CBZ was 
varied at three levels: 10, 15 and 20 %. Dissolution rate profiles of the selected optimal for-
mulation were compared with pure CBZ and commercially available immediate release CBZ 
tablets (Galepsin®, Galenika a.d, Serbia). 
In vitro drug release studies 
The dissolution profiles of the different solid surfactant systems and pure CBZ were 
determined using a rotating paddle apparatus (Erweka DT70, Germany). The dissolution 
conditions were: water as medium; 37±0.5 °C; 900 mL and 50 rpm. Aliquots of 4 mL were 
withdrawn from the medium at fixed times (10, 20, 30, 45, 60 and 120 min). Sink conditions 
were maintained at all times. All samples were filtered through a 0.45-µm MF-Millipore® 
membrane filter (Millipore Corporation, Bedford, NY, USA). The CBZ concentration was 
determined spectrophotometrically at λ = 287 nm (Evolution 300 spectrophotometer, Thermo 
Fisher Scientific, UK). The dissolution experiments were performed in triplicate and the data 
are expressed as the mean value. 
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The release profiles of CBZ from solid surfactant systems were compared with the 
dissolution profiles of pure CBZ by calculating the difference (f1) and the similarity (f2) 
factors.32 
Characterization of the solid phase 
In order to determine the polymorphous form of CBZ in the final formulation and the 
influence of individual excipients on the change in the polymorphous form, DSC and TGA 
analyses were conducted in the first set of experiments. DSC, TGA, X-ray and FT-IR analyses 
were performed on the optimal formulation and pure CBZ. 
The optimal formulation was kept under room conditions (T 25 °C and RH 40 %) for 
three months in order to assess its stability, after which the DSC, TGA, X-ray and FT-IR 
analyses were repeated. 
Differential scanning calorimetry (DSC) and thermal gravimetric analysis (TGA)  
Differential scanning calorimetry (DSC) and thermal gravimetric analysis (TGA) were 
applied in order to determine thermal properties of the compounds. Thermal properties were 
examined at temperatures ranging from room temperature up to 250 °C on a SDT Q600 TGA/  
/DSC instrument (TA Instruments) under a dynamic dry nitrogen atmosphere (flow rate: 100 
cm3 min-1) at a heating rate of 20 °C min-1. The sample masses were between 7.3 and 11.5 mg. 
Fourier transform infrared (FT-IR) studies 
FT-IR spectra in the region of 600–4000 cm-1 for both starting materials and the solid 
formulations were obtained using a Shimadzu IR-Prestige-21 FT-IR spectrometer coupled 
with a horizontal Golden Gate MKII single-reflection ATR system (Specac, Orpington, UK) 
equipped with a ZnSe lens, after appropriate background subtraction. Sixteen scans over the 
selected wave number range at a resolution of 4 cm-1 were averaged for each sample. 
Powder X-ray diffraction analysis (PXRD)  
The X-Ray diffraction (PXRD) patterns of the powders were recorded on an Ital Struc-
ture APD2000 X-ray diffractometer with Bragg–Brentano geometry using CuKα radiation 
(λ =1.5418 Å) in the 2θ range from 4 to 45°. 
RESULTS AND DISCUSSION 
CBZ release profiles from the binary and ternary mixtures prepared in the 
first set of experiments, as well as the release profile of the pure drug, are pre-
sented in Fig. S-1 of the Supplementary material. The CBZ release was increased 
in all mixtures compared to that of the pure drug. Similarity and difference fac-
tors were calculated for all mixtures (Table II). 
TABLE II. The difference (f1) and the similarity (f2) factors for the mixtures and pure CBZ 
(from the first set of experiments). The percentage mass loss in the temperature range 100– 
–200 °C for the mixtures prepared in the first set of experiments 
Mixtures f1 f2 Mass loss, % 100 °C < T < 200 °C 
CBZ & CBZ+Brij® 35 8.32 62.15 7.31 
CBZ & CBZ+Brij® 35+ Neusilin® UFL2 23.14 36.41 4.34 
CBZ & CBZ+P338 51.41 9.15 0.19 
CBZ & CBZ+P338+ Neusilin® UFL2 57.98 3.38 4.31 
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Based on the results presented in Table II, it could be concluded that the 
CBZ dissolution rate was statistically significantly increased in following mix-
tures: Brij® 35/CBZ/Neusilin® UFL2 (40/10/50), Poloxamer 338/CBZ (80/20) 
and Poloxamer 338 /CBZ /Neusilin® UFL2 (40/10/50). The CBZ dissolution rate 
in the mixture Brij® 35/CBZ (80/20) was similar to that of pure CBZ dissolution. 
The increase in the CBZ dissolution rate with the addition of Poloxamer 338 
was expected because of its high hydrophilic–lipophilic balance (HLB) value 
(HLB-27) and solubility characteristics.33 The adsorbent carrier with its large 
specific surface leads to better soaking of the substance and more contact with 
the medium, which also increases the CBZ dissolution rate.34 The addition of 
Poloxamer 338 had more effect individually than the addition of Brij® 35, which 
was expected due to its lower HLB value of 16 in comparison to 27 for Polox-
amer 338.33 Therefore, Brij® 35 was used as a co-surfactant in the second set of 
experiments. 
The CBZ dissolution rate profiles obtained from the second set of experi-
ments are given in Fig. 1. Significant increases in the dissolution rate were regis-
tered compared to that of pure CBZ. 
 
Fig. 1. Dissolution profiles of the CBZ formulation prepared in the second set of experiments 
and pure CBZ. 
The calculated factor effects (Eq. (1)) are given in Table III. The sign of the 
coefficient shows whether the effect is positive or negative, i.e., whether the CBZ 
dissolution rate increases (positive effect) or decreases (negative effect) with a 
change in the parameter value.  
The CBZ ratio (X3) had the most pronounced influence on the drug release 
in the first 10 min of the drug release study. This parameter had a negative effect 
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because of the poor solubility of CBZ. The percentage of released CBZ dec-
reased with increasing of its ratio in the formulation (from 10 to 20 %). 
TABLE III. Analysis of the influence of the input parameters on the output parameter, 
released CBZ, %, in the second set of experiments 
Factor effect τ / min 
10 (Y1) 20 (Y2) 30 (Y3) 45 (Y4) 60 (Y5) 120 (Y6) 
X1 (type of Poloxamer)  +1.09 +0.31 +1 +1.01 +1.15 0.9 
X2 (Brij® 35 ratio)  –1.8 –2.02 –1.31 –1.47 –1.23 0.037 
X3 (CBZ ratio) –6.45 –5.8 –5.12 –4.6 –3.86 –3.02 
X4 (type of adsorption carrier) –3.17 –5.13 –6.26 –6.15 –5.77 –5.72 
X5 (adsorption carrier ratio) –5.87 –4.16 –3.53 –3.15 –3.55 –2.33 
X2 and X3 interaction –3.23 –2.57 –1.99 –1.81 –1.62 –1.26 
X2 and X5 interaction +3.31 +1.55 +0.8 +0.24 +0.16 –0.14 
After 30 min of the drug release study, the type of carrier had more inf-
luence. Initially, CBZ was released from the surfaces of both carriers. Due to the 
larger specific surface area of Neusilin® UFL2 (300 m2 g–1) compared to diato-
mites (211 m2 g–1), a higher CBZ release rate was achieved 22,35,36 and the 
significance of this factor increased with time. In solid surfactant systems with 
diatomites, due to their specific structure, the substance is absorbed into the inter-
ior of the diatomite, from where it is gradually released;37,38 hence, the CBZ rel-
ease was delayed as the release had to occur from the interior of the system. 
It was shown that the higher carrier ratio had a negative impact on drug 
release. A higher release rate was achieved when the carrier ratio was at its lower 
level (33.33 %). According to Agarwal et al.,35 the adsorbent magnesium alu-
minometasilicate, with a large specific active surface (300 m2 g–1) and small 
particle size (2−8 μm), has pores in which an adsorbed substance could enter by 
means of capillary forces. Inside the pores, potential crystallization is disabled. It 
could be presumed that the decrease in the dissolution rate after adsorption 
derives from the precipitation of the drug on the surface of the adsorbent and the 
capturing of the drug inside the carrier. This was particularly evident after 10 and 
20 min, when the percentage of the substance to be released was low, due to the 
poor availability of CBZ to the medium. 
The type of employed Poloxamer had the least pronounced influence on the 
CBZ release rate. The systems created with Poloxamer 338 (HLB 27) showed a 
slightly higher CBZ release rate compared to those of the Poloxamer 237 systems 
(HLB 24), which, was expected, due to the higher HLB value of the former.33 
Poloxamer 338 also has a lower value of the critical micellar concentration 
(CMC) compared to Poloxamer 237 and is, therefore, a more efficient solubilizer, 
which corresponds to the obtained result (the CMC of Poloxamer 338 is 2.2×10–5 
mol L–1 while that of Poloxamer 237 is 9.1×10–5 mol L–1).39,40 
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Comparing the obtained factor effects from Eq. (1), it is evident that the 
Brij® 35 ratio had less influence on the CBZ release rate. The formulation with 
the higher Brij® 35 ratio had a lower Poloxamer ratio. In the first set of experi-
ments, it was shown that the Poloxamer had a greater influence on the increase in 
the CBZ dissolution rate compared to Brij® 35. However, there was a significant 
interaction between the CBZ ratio and the ratio of Brij® 35. Formulations with a 
higher level of the CBZ ratio and a lower level of Brij® 35 showed the highest 
percentages of released CBZ. 
The analysis revealed another significant interaction, i.e., that of the ratios of 
Brij® 35 and the carrier ratio. When the carrier ratio was at the lowest level, a 
change of the Brij® 35 ratio from 10 to 20 % decreased the percentage of rel-
eased substance. From the previous interaction, it could be concluded that higher 
release rates were achieved with 10 % of Brij® 35 in the formulation. In this 
case, a higher substance release rate was achieved when the carrier ratio was at 
the lower level, i.e., 33.33 %. 
From second set of experiments, the selected: Poloxamer 338, Brij® 35 10 %, 
Neusilin UFL2 33.33 % formulation exhibited the highest CBZ release rate. In 
such a solid surfactant system, the CBZ ratio was set at 10, 15 and 20 %. The 
results of drug release study from these formulations are shown in Fig. S-2A of 
the Supplementary material.  
The highest percentage of released CBZ was obtained from the formulation 
with 15 % of CBZ. The CBZ drug release profile from this formulation is com-
pared with the profiles of pure CBZ and commercially available immediate rel-
ease CBZ tablets in Fig. S-2B of the Supplementary material.  
The results of the TGA analysis (Fig. 2A) showed that in the temperature 
range of 100 to 200 °C, Neusilin® UFL2 exhibited a mass loss of about 8.5 %, 
whereas the optimal formulation lost 4.31 % of its mass. The mass loss for samp-
les prepared in the first set of experiments in the temperature range of 100 to 200 
°C are presented in Table II. CBZ exhibited a small mass loss within the tem-
perature range of 100 to 200 °C, while in the range of 200 to 250 °C, an imme-
diate mass loss of 2.5 % was registered, probably indicating the commencement 
of its degradation. A somewhat higher loss of mass was registered in the samples 
in which Brij® 35 was used as the surfactant. Moreover, a significant decrease in 
mass of all samples was registered in the temperature range of 200 to 250 °C, 
which correlates with the result obtained for pure CBZ (Fig. 2B). 
The DSC curves of the tested samples and pure CBZ showed an endothermic 
peak at about 60 °C (Fig. 2C). Bearing in mind the very broad range over which 
the device was calibrated (60–800 °C), this peak could derive from measurement 
uncertainty, i.e., the imprecision of the instrument. With formulations containing 
Poloxamer, this peak was somewhat more distinct, because their peak derives 
from the melting of Poloxamer.41 This led to an overlapping of the peaks in these 
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formulations. Based on the two endothermic peaks at 178 and 195.6 °C, it could 
be concluded that the pure CBZ was in the polymorphous form III.31,42 The 
reason for these peaks occurring at higher temperatures than those given in the lite- 
 
Fig. 2. A) TGA curves of pure CBZ, Neu-
siline UFL2 and the optimal formulation; 
B) TGA curves of the mixtures prepared in 
the first set of experiments; C) DSC curves 
of pure CBZ, the optimal formulation and 
the mixtures prepared in the first set of 
experiments. 
rature31 could be explained by the higher heating rate employed in the present 
study (20 °C min–1) than the rate used in the literature study (10 °C min–1), i.e., 
the difference in the temperature lag of the two systems. The balance of the 
system was achieved slightly later and, therefore, the changes identified by the 
peaks were delayed by a few °C. In addition, because of the difference in the 
experimental conditions, no distinct recrystallization peak corresponding to the 
transition of the sample into the polymorphous form I was visible on the DSC 
curve of pure CBZ recorded in the present study. Furthermore, on the DSC 
curves of the samples, a broad endothermic peak was registered in the tempera-
ture range 230–240 °C. It is assumed that this peak corresponded to the begin-
ning of CBZ degradation, which is in accordance with the results of the TGA 
analysis. From this point of view, an analysis of the degradation products and the 
further clarification of this peak could be a part of further investigations. In all 
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four tested mixtures, no characteristic melting peaks from polymorphous form III 
were evidences in the temperature range of 150 to 175.8 °C.31,42 In addition, no 
peaks characteristic for other polymorphous forms were registered. Thus, it could 
be assumed that a transition of CBZ from the crystal polymorphous form III into 
amorphous form had occurred. It is notable that the application of the individual 
surfactants (Poloxamer 338 and Brij® 35, with or without the addition of Neusi-
lin® UFL2) led to the transition of CBZ into the amorphous form. Although DSC 
is a commonly used technique for the determination of crystalline state of drugs 
and the absence of a melting peak might suggest the formation of an amorphous 
phase,43 care should be taken in the interpretation of the results of DSC analysis, 
particularly when the formulations contain a Poloxamer. Since poloxamers melt 
at significantly lower temperatures than CBZ, there is a possibility that crystal-
line CBZ gradually dissolves into a molten polymer during the DSC scan. As the 
temperature reaches the melting point of CBZ, there may not be sufficient crys-
talline drug remaining to give a detectable melting endotherm on the DSC 
curve.44 Therefore, further characterization of the optimal formulation was per-
formed by application of PXRD and FT-IR analysis in order to confirm the trans-
ition of the drug into the amorphous form. 
The FT-IR spectra of CBZ and the optimal formulation are given in Fig. 3A 
and B, respectively. The CBZ spectrum corresponds to those previously reported 
for the polymorph form III. Characteristic peaks were observed at 3462 (−NH 
valence vibration), 1674 (−CO−R vibration), 1593 and 1605 cm–1 (in the range 
of −C=C− and −C=O vibration and −NH deformation).31 Deformation of bands 
characteristic for the CBZ form III at 1605 and 1593 cm−1 (−C=O vibration and 
−NH deformation) (Fig. 3B.) in FT-IR spectra of the optimal formulation may 
suggest that a hydrogen bond between the carbonyl group of CBZ and silanol 
group of adsorbent participate in the formation of the amorphous state of CBZ. 
There have been reports of drug amorphization by co-grinding with porous silica 
or magnesium aluminometasilicate.24–26 Drug amorphization was accompanied 
by improvement in the drug release rate. CBZ amorphization is a consequence of 
disruption of the crystalline structure due to hydrogen bonds formation between 
the drug and adsorbent. 
The PXRD patterns of pure CBZ and the optimal formulation are illustrated 
in Fig. 4. The PXRD pattern of CBZ exhibits characteristic high-intensity dif-
fraction peaks at 2θ 13.02, 15.22, 15.78, 19.40, 24.92, 27.50 and 31.86°, which is 
in accordance with diffractograms previously reported for the crystal form III.31,45 
These characteristic peaks cannot be seen on the diffractogram of the optimal 
formulation, which confirms the results obtained by DSC and FT-IR analysis that 
the carbamazepine had transformed into the amorphous form. The two broad 
peaks appearing on the diffractogram of the optimal formulation arose from Pol-
oxamer 338.46 
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Fig. 3. FT-IR spectra of A) pure 
CBZ and B) the optimal formul-
ation. 
Fig. 4. PXRD patterns of A) 
pure CBZ and B) the opti-
mal formulation. 
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DSC, TGA, FT-IR and PXRD analyses of the optimal formulation that had 
been kept under ambient conditions for three months showed no significant 
changes in the formulation had occurred. The CBZ remained in the amorphous 
state and the stability of the formulation was thus confirmed. 
CONCLUSIONS 
Formulation of solid surfactant drug delivery systems with CBZ as a model 
drug showed that the addition of Poloxamer (237 or 338), Brij® 35 and an adsor-
bent (Neusilin UFL2 or diatomite) led to the transition of CBZ into the amor-
phous state and an increase in its release rate. Poloxamers, as surfactants, had the 
most significant effect on the increase of the drug release rate. The addition of 
the adsorbent carrier further increased the CBZ release rate, due to its large spe-
cific surface. 
The highest carbamazepine release rate was obtained from the optimal for-
mulation in which the surfactant mixture had the following components: 75 % 
Poloxamer 338; 10 % Brij® 35; 15 % CBZ, while the surfactant mixture and 
Neusilin® UFL2 as carrier were in 2:1 ratio. This formulation was stable for at 
least three months.  
From all the presented results, it could be concluded that the release rate of 
poorly soluble CBZ could be increased by solid surfactant systems. 
SUPPLEMENTARY MATERIAL 
Experimental plan for the second set of experiments, Table S-I, and dissolution profiles 
of the mixture and CBZ formulation, Figs. S-1 and S-2, are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
ЕКСПЕРИМЕНТАЛНИ ДИЗАЈН ИСПИТИВАЊА БРЗИНЕ РАСТВАРАЊА 
КАРБАМАЗЕПИНА ИЗ ФОРМУЛАЦИЈА. КАРАКТЕРИЗАЦИЈА ОПТИМАЛНЕ 
ФОРМУЛАЦИЈЕ ПОМОЋУ DSC, TGA, FT-IR И PXRD МЕТОДА 
МАРКО КРСТИЋ1, СЛАВИЦА РАЖИЋ2, ДРАГАНА ВАСИЉЕВИЋ1,ЂУРЂИЈА СПАСОЈЕВИЋ1 и СВЕТЛАНА ИБРИЋ1 
1Катедра за фармацеутску технологију и козметологију, Универзитет у Београду, Фармацеутски 
факултет, Војводе Степе 450, 11221 Београд и 2Катедра за аналитичку хемију, Универзитет у 
Београду, Фармацеутски факултет, Војводе Степе 450, 11221 Београд 
Слаба растворљивост јесте један од кључних разлога за лошу биолошку располо-
живост карбамазепина. У овом раду је приказана формулација чврстих површински 
активних система са карбамазепином, ради повећања његове брзине растварања. Чврсти 
површински активни системи су формулисани применом фракционог факторског екс-
перименталног дизајна. Као површински активни системи коришћени су Poloxamer 237 
и Poloxamer 338, а као ко-површински активни Brij® 35. Варирани су удели ексципи-
јенаса и карбамазепина и испитиван је њихов утицај на брзину растварања карбамазе-
пина. Такође, испитан је и утицај додатка природних (дијатомита) и синтетичких адс-
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орпционих носача (Neusilin UFL2) на брзину ослобађања карбамазепина. Извршена је 
карактеризација израђених површински активних система и испитан је утицај ексци-
пијенаса на могућу промену полиморфног облика карбамазепина применом аналитич-
ких техника (DSC, TGA, FT-IR и PXRD). Утврђено је да се правилним одабиром врсте и 
удела ексципијенаса може постићи значајно повећање брзине ослобађања карбамазе-
пина. Аналитичким техникама је утврђено да коришћени ексципијенси доводе до пре-
ласка карбамазепина у аморфни облик и да је одабрани узорак стабилан 3 месеца, чува-
њем под собним условима. 
(Примљено 3. августа, ревидирано 14 новембра, прихваћено 15. новембра 2014) 
REFERENCES 
1. M. S. Ku, W. Dulin, Pharm. Dev. Technol. 17 (2012) 285 
2. C. Pouton, Eur. J. Pharm. Sci. 29 (2006) 278 
3. J. Y. Kim, Y. S. Ku, Int. J. Pharm. 194 (2000) 81 
4. A. J. Humberstone, W. N. Charman, Adv. Drug Deliv. Rev. 25 (1997) 103 
5. C. Leuner, J. Dressman, Eur. J. Pharm. Biopharm. 50 (2000) 47 
6. G. Serajuddin, A. T. M., Adv. Drug Deliv. Rev. 34 (2007) 34 
7. J. C. Chaumeil, Methods Find. Exp. Clin. Pharmacol. 20 (1998) 211 
8. S. M. Ali, S. K. Upadhyay, A. Maheshwari, J. Incl. Phenomena Macrocycl. Chem. 59 
(2007) 351 
9. R. N. Gursoy, S. Benita, Biomed. Pharmacother. 58 (2004) 173 
10. L. Wang, J. Dong, J. Eastoe, X. Li, J. Colloid Interf. Sci. 330 (2009) 443 
11. M. Milovic, J. Djuris, Lj. Djekic, D. Vasiljevic, S. Ibric, Int. J. Pharm. 436 (2012) 58 
12. M. Milovic, J. Djuris, D. Vasiljevic, Z. Djuric. S. Ibric, Hem. Ind. 66 (2012) 667 
13. D. Vasiljevic, J. Parojcic, M. Primorac, G. Vuleta, J. Serb. Chem. Soc. 74 (2009) 801 
14. J. H. Collett, In: Handbook of Pharmaceutical Excipients, 6th ed., R. C. Rowe, P. J. 
Sheskey, M. E. Quinn, Eds., Pharmaceutical Press, London, 2009, p. 506 
15. G. Dumortier, J. L. Grossiord, F. Agnely, J. C. Chaumeil, Pharm. Res. 23 (2006) 2709 
16. N. Kolašinac, K. Kacrimanis, I. Homšek, B. Grujić, Z. Đurić, S. Ibrić, Int. J. Pharm. 436 
(2012) 161 
17. A. V. Shah, A. T. Serajuddin, Pharm. Res. 29 (2012) 2817 
18. M. S. Mesiha, H. E. Bitar, J. Pharm. Pharmacol. 33 (1981) 733 
19. Y. Hua, H. Y. Qing, C. F. Fanny, Z. Zhong, H. Yi Fan ,Y. Nancy, Biopharm. Drug 
Dispos. 32 (2011) 140 
20. A. A. Attama, I. J. Ayogu, F. C. Kenechukwu, J. D. N. Ogbonna, V. C. Okore, Int. J. 
Drug Delivery 3 (2011) 743 
21. V. Jannin, J. Musakhanian, D. Marchaud, Adv. Drug Delivery Rev. 60 (2008) 734  
22. M. Sinn Aw, S. Simovic, Y. Yu, J. Addai-Mensah, D. Losic, Nanomedicine 6 (2011) 
1159  
23.  D. Losic, J. G. Mitchell, N. H. Voelcker, Adv. Mater. 21 (2009) 2947 
24.  O. Planinšek, V. Kovačić, F. Vrečer, Int. J. Pharm. 406 (2011) 41 
25. D. Bahl, R. H. Bogner, AAPS Pharm. Sci. Tech. 9 (2008) 146 
26. M. Gupta, V. Adam, R. Bogner, J. Pharm. Sci. 92 (2003) 536 
27. Y. Kobayashi, S. Itai, K. Yamamoto, Int. J. Pharm. 193 (2000) 137 
28. S. Sethia, E. Squillante, J. Pharm. Sci. 91 (2002) 1948 
29. G. L. Amidon, R. Löbenberg, Eur. J. Pharm. Biopharm. 50 (2000) 3 
30. C. Xu, M. Zou, Y. Liu, J. Ren, Y. Tian, J. Yan, Y. Wang, G. Cheng, Arch. Pharm. Res. 
34 (2011) 1973 
_________________________________________________________________________________________________________________________
(CC) 2015 SCS. All rights reserved.
Available on line at www.shd.org.rs/JSCS/
222 KRSTIĆ et al. 
31. A. Grzesiak, M. Lang, K. Kim, A. Matzger, J. Pharm. Sci. 92 (2003) 2261 
32. Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms, U.S. Department of Health and Human Services, Food and Drug Administration, 
Center for Drug Evaluation and Research (CDER), 1997 
33. Solubility Enhancement with BASF Pharma Polymers, Solublizer Compendium, BASF, 
http://www.pharma-ingredients.basf.com/ (accessed 1.7.2014) 
34. Y. Ito, H. Arai, K. Uchino, K. Iwasaki, N. Shibata, K. Takada, Int. J. Pharm. 289 (2005) 69 
35. V. Agarwal, A. Siddiqui, H. Ali, S. Nazzal, Int. J. Pharm. 366 (2009) 44 
36. A. Krupa, D. Majda, R. Jachowicz, W. Mozgawa, Thermochim. Acta 509 (2010) 12 
37. H. Elde, G. Morsy, M. Bakr, Asian J. Mater. Sci. 2 (2010) 121 
38. M. Bariana, M. S. Aw, M. Kurkuri, D. Losic, Int. J. Pharm. 443 (2013) 230 
39. E. Batrakova, S. Lee, S. Li, A. Venne, V. Alakhov, A. Kabanov, Pharm. Res. 16 (1999) 
1373 
40. A. V. Kabanov, I. R. Nazarova, I. V. Astafieva, E. V. Batrakova, V. Y. Alakhov, A. A. 
Yaroslavov, V. A. Kabanov, Macromolecules 28 (1995) 2303 
41. P. J. Marsac, T. Li, L. S. Taylor, Pharm. Res. 26 (2009) 139 
42. L. Yu, S. M. Reutzel-Edens, C. A. Mitchell, Org. Process Res. Dev. 4 (2000) 396 
43. C. Leuner, J. Dressman, Eur. J. Pharm. Biopharm. 50 (2000) 47 
44. M. Yang, P. Wang, C. Y. Huang, M. S. Ku, H. Liu, C. Gogos, Int. J. Pharm. 395 (2010) 53 
45. C. Rustichelli, G. Gamberini, V. Ferioli, M. C. Gamberini, R. Ficarra, S. Tommasini, J. 
Pharm. Biomed. Anal. 23 (2000) 41 
46.  W. Ali, A. C. Williams, CF. Rawlinson, Int. J. Pharm. 391 (2010) 162. 
_________________________________________________________________________________________________________________________
(CC) 2015 SCS. All rights reserved.
Available on line at www.shd.org.rs/JSCS/
